CN105362238A - 一种依诺肝素注射制剂及其工业化生产方法 - Google Patents
一种依诺肝素注射制剂及其工业化生产方法 Download PDFInfo
- Publication number
- CN105362238A CN105362238A CN201510956118.6A CN201510956118A CN105362238A CN 105362238 A CN105362238 A CN 105362238A CN 201510956118 A CN201510956118 A CN 201510956118A CN 105362238 A CN105362238 A CN 105362238A
- Authority
- CN
- China
- Prior art keywords
- insulation
- dividing plate
- warming
- stage
- vacuum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960000610 enoxaparin Drugs 0.000 title claims abstract description 23
- 238000002347 injection Methods 0.000 title claims abstract description 20
- 239000007924 injection Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000009776 industrial production Methods 0.000 title abstract 3
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 claims abstract description 40
- 229960005153 enoxaparin sodium Drugs 0.000 claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 238000009413 insulation Methods 0.000 claims description 62
- 238000010792 warming Methods 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000008215 water for injection Substances 0.000 claims description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 229930195725 Mannitol Natural products 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 239000003610 charcoal Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 238000005057 refrigeration Methods 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229940105082 medicinal charcoal Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000007689 inspection Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 229920005556 chlorobutyl Polymers 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229950000845 politef Drugs 0.000 claims description 3
- 229910001868 water Inorganic materials 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940027278 hetastarch Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000013067 intermediate product Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002373 hemiacetals Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510956118.6A CN105362238B (zh) | 2015-12-18 | 2015-12-18 | 一种依诺肝素注射制剂及其工业化生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510956118.6A CN105362238B (zh) | 2015-12-18 | 2015-12-18 | 一种依诺肝素注射制剂及其工业化生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105362238A true CN105362238A (zh) | 2016-03-02 |
CN105362238B CN105362238B (zh) | 2019-03-19 |
Family
ID=55365199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510956118.6A Active CN105362238B (zh) | 2015-12-18 | 2015-12-18 | 一种依诺肝素注射制剂及其工业化生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105362238B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107041870A (zh) * | 2017-04-06 | 2017-08-15 | 泰山医学院 | 一种预防运动创伤手术后静脉血栓的注射液及其制备方法 |
CN108888592A (zh) * | 2018-06-19 | 2018-11-27 | 南京南大药业有限责任公司 | 一种低分子量肝素钠注射液及其制备方法 |
CN112656767A (zh) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | 一种依诺肝素钠注射制剂及其制备方法 |
CN113069414A (zh) * | 2021-04-06 | 2021-07-06 | 山东万邦赛诺康生化制药股份有限公司 | 一种肝素钠注射液的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175693A1 (en) * | 2002-05-09 | 2005-08-11 | Peptron Co., Ltd | Substained release formulation of protein and preparation method thereof |
US20070116729A1 (en) * | 2005-11-18 | 2007-05-24 | Palepu Nageswara R | Lyophilization process and products obtained thereby |
CN101612130A (zh) * | 2009-07-16 | 2009-12-30 | 江苏万邦生化医药股份有限公司 | 注射用低分子量肝素钠的制备工艺 |
CN105030702A (zh) * | 2015-07-15 | 2015-11-11 | 马鞍山丰原制药有限公司 | 一种含肝素钠药物组合物及其制备方法 |
-
2015
- 2015-12-18 CN CN201510956118.6A patent/CN105362238B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175693A1 (en) * | 2002-05-09 | 2005-08-11 | Peptron Co., Ltd | Substained release formulation of protein and preparation method thereof |
US20070116729A1 (en) * | 2005-11-18 | 2007-05-24 | Palepu Nageswara R | Lyophilization process and products obtained thereby |
CN101612130A (zh) * | 2009-07-16 | 2009-12-30 | 江苏万邦生化医药股份有限公司 | 注射用低分子量肝素钠的制备工艺 |
CN105030702A (zh) * | 2015-07-15 | 2015-11-11 | 马鞍山丰原制药有限公司 | 一种含肝素钠药物组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
林剑萍: "依诺肝素的临床应用", 《中国现代药物应用》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107041870A (zh) * | 2017-04-06 | 2017-08-15 | 泰山医学院 | 一种预防运动创伤手术后静脉血栓的注射液及其制备方法 |
CN108888592A (zh) * | 2018-06-19 | 2018-11-27 | 南京南大药业有限责任公司 | 一种低分子量肝素钠注射液及其制备方法 |
CN112656767A (zh) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | 一种依诺肝素钠注射制剂及其制备方法 |
CN113069414A (zh) * | 2021-04-06 | 2021-07-06 | 山东万邦赛诺康生化制药股份有限公司 | 一种肝素钠注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105362238B (zh) | 2019-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105362238A (zh) | 一种依诺肝素注射制剂及其工业化生产方法 | |
CN105078906A (zh) | 一种含尿激酶的药物冻干制剂及其制备方法 | |
CN102133199A (zh) | 注射用多索茶碱冻干制剂及其制备方法 | |
CN103382232A (zh) | 那曲肝素钙的制备及纯化工艺 | |
CN101703484B (zh) | 一种地塞米松磷酸钠冻干粉针剂的制备方法 | |
CN105979949A (zh) | 不含抗氧化剂的药物组合物及其制备方法 | |
CN102258488B (zh) | 一种注射用克林霉素磷酸酯组合物及其制备方法 | |
CN102813908A (zh) | 一种制备注射用比伐卢定的冻干工艺 | |
CN103386117A (zh) | 一种低杂质含量的卡泊芬净制剂及其制备方法和用途 | |
CN113197870B (zh) | 一种注射用丝裂霉素冻干制剂及其制备方法 | |
CN101972248B (zh) | 一种供注射用的法莫替丁组合物及其制备方法 | |
CN101947208A (zh) | 一种供注射用的磷酸氟达拉滨组合物及其制备方法 | |
CN101897672A (zh) | 一种注射用阿昔洛韦冻干制剂的制备方法 | |
CN102058548B (zh) | 一种供注射用的盐酸氨溴索组合物及其制备方法 | |
CN102423484A (zh) | 一种稳定的西曲瑞克药物组合物及其制备方法 | |
CN108606955A (zh) | 培化西海马肽的药用组合物及其制备方法 | |
CN105796509A (zh) | 一种倍他米松磷酸钠冻干粉针剂的制备方法 | |
CN105079015B (zh) | 曲克芦丁冻干粉针剂及其制备方法 | |
CN104013570A (zh) | 一种依诺肝素钠注射液及其制备工艺 | |
CN105343019A (zh) | 一种卡络磺钠冻干粉针剂的制备方法 | |
CN112137969A (zh) | 含有依诺肝素钠的注射用依诺肝素钠及其制备方法 | |
CN103735522B (zh) | 一种炎琥宁冻干粉针及其制备方法 | |
CN103505423B (zh) | 盐酸溴己新冻干粉针剂及其制备方法 | |
CN105030702A (zh) | 一种含肝素钠药物组合物及其制备方法 | |
CN103054816A (zh) | 抑肽酶冻干粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221205 Address after: 10/F, Building B7, Tianfu Life Science Park, No. 88, South Keyuan Road, Hi tech Zone, Chengdu, Sichuan 610000 Patentee after: Sichuan Hongming Bosi Pharmaceutical Co.,Ltd. Address before: 610000 Chengdu cross strait Science Park, Wenjiang District, Chengdu, Sichuan Patentee before: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An injection preparation of enoxaparin and its industrial production method Effective date of registration: 20231228 Granted publication date: 20190319 Pledgee: Chengdu small business financing Company Limited by Guarantee Pledgor: Sichuan Hongming Bosi Pharmaceutical Co.,Ltd. Registration number: Y2023980074980 |